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-)ng-Term Survival of Heart and Liver Xenografts With Splenectomy 
ld FK 506 
Celli, L.A. Valdivia, J.J. Fung, A.J. Demetris, I.A. Marino, N. Murase, and T.E. Starzl 
VE HAVE reported that while hamster-to-rat liver 
xenograft survival is prolonged by FK 506, ham-
. hearts undergo humoral rejection under thisimmuno-
pressant. I Because the spleen has been shown to be 
: of the main sources of xenoantibodies,2.3 and in vivo 
'eriments have demonstrated that splenectomy (Spx) is 
;! to increase the efficacy of various immunosuppressive 
nts after xenotransplantation.4-6 we combined Spx 
h FK 506 to test whether survival of the intractable 
jiac xenografts is prolonged, and of liver xenografts 
'roved. 
TERIALS AND METHODS 
'is rats (250 to 280 g) and Golden Syrian hamsters (120 to 180 
ere used as recipients and donors. respectively. Heterotopic 
:t transplantation (HTx) was performed according to the 
hod of Ono and Lindsey, while orthotopic liver transplanta-
(OLn was performed according to the cuff technique. 
!nectomy (Spx) was performed at the end of the transplant 
ration. The animals were divided in 12 groups, as shown in the 
Ie 1. 
complement-dependent cytotoxicity test (CDC) was used 
ally to detect. in the recipient's serum. the amount of antiham-
antibodies following heart and liver transplantation. Grafts of 
!rent groups were studied with light microscopy to create a 
tionship between the immunosuppressive therapy and the 
·ence of rejection. At 100 days after transplantation. two 
animals in group 6 received intravenously 0.5 mL of serum taken 
from a group I rat at the time of rejection. 
RESULTS 
Table I shows xenograft survival. Among the animals that 
received heart transplantation, the best results were 
achieved with the combination of Spx and FK 506 2 
mg/kgld (group 6). In this group, all grafts survived beyond 
100 days. The therapy with FK 506 I mglkgld + Spx was 
effective in only two animals. Spx or FK 506 alone. even at 
high doses, did not significantly prolong the survival of the 
transplanted hearts. Among the animals that received liver 
transplantation. the best results were obtained with Spx + 
FK 506 1 mg/kg/d (group 11). Group 12, that received Spx 
+ 2 mg/kgld of FK 506, showed poorer results than group 
11 and the groups that received FK 506 alone. In groups 8. 
9, 11, and 12, all animals that died had severe jaundice and 
biliary dilatation at autopsy. In these cases, the histologi-
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Table 1. Survival of Hamster Cardiac and Liver Xenografts In Lewis Rat Recipients 
100-Day 
lp Treatment N Graft Survival Days Survival Percent 
Untreated 6 3,3,3,3,3,3 0/6 0% 
FK 506 1 mg/kg/d 6 3,3,3,3,3,4 0/6 0% 
FK 506 2 mg/kg/d 6 4,4,4,4,5.5 0/6 0% 
Spx 6 5,5,5,5,5,5 0/6 0% 
Spx + FK 1 mg/kg/d* B 6,7,7,7, 7,B, >100,>100 2IB 25% 
Spx + FK 2 mg/kg/dt 10 >100 x 10 10/10 100% 
Untreated 8 6,7,7,7,7,7,7,B 0/8 0% 
FK 506 1 mg/kgld* 10 12,20,27,29, 33, 4B, 66, >100 x 3 3110 30% 
FK 506 2 mg/kg/d* 10 10,13,20,23,34,34.50, >100 x 3 3110 30% 
J. Spx 8 7, 7, 7, 7, 7, 7, B, B O/B 0% 
. Spx + FK 1 mg/kgld* 10 9,21,26,40, 4B, >100 x 5 5/10 50% I. 
~. spx + FK 2 mg/kgld* B 7,9,9,12,17,20,30,31 0/8 0% 
K 506 was administered in a dose of I mglkgJd during the first month. and then 0.5 mglkg every other day. stopping treatment on day 100. 
K 506 2 mglkgld x 15. then I mglkg until day 30. then 0.5 every other day until day 100. 
K 506 was given in a dose of 2 mglkgld for the first month, then 0.5 mg/kg every other day until day 100. 
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cal study showed important biliary proliferation without 
signs of rejection. Heterophilic antibody production after 
cardiac xenografting was completely suppressed in group 6 
(combined treatment). The recipients of the other groups 
showed peaks of antibody titers around the third postop-
erative day (range 1:8 to 1:512). In contrast, all animals 
that underwent liver transplantation developed high titers 
of cytotoxic antibodies around the seventh postoperative 
day (range 1 :512 to 1 :8182). Lower titers were found in the 
group treated with Spx -and 1 mg/kg/d of FK 506 (l: 128) . 
Cytotoxicity in the serum of long-term survival liver recip-
ients became negative by 3 to 4 weeks, regardless of the 
treatment. Long-term surviving cardiac xenografts which 
received hyperimmune antihamster serum underwent hy-
peracute rejection 3 minutes after injection. 
DISCUSSION 
Splenectomy seems to have a different impact after liver or 
heart xenotransplantation. While after heart xenografting, 
Spx + FK 506 2 mglkg/d resulted in long-term graft 
survival in all recipients, confirming Carobbi's experi-
ments.7 with the same therapy the percentage of long-term 
surviving liver xenografts was zero. The best protocol of 
immunosuppression for liver xenografts proved to be Spx 
+ 1 mg/kgld FK 506. However. even with this therapy. 
lOO-day recipient survival was increased to only 50%. In 
both liver and heart xenotransplantation, there was a 
correlation between the presence of cytotoxicity in the 
serum of xenograft recipients and graft survival. Absence 
of cytotoxicity resulted in long-term survival. In contrast. 
high cytotoxic activity in the recipient sera meant rejection 
in the heart recipients-but only hepatic damage in the 
liver recipients. In fact, liver xenograft recipients that died 
while under treatment had severe jaundice with biliary 
dilatation. The histological findings of the liver grafts 
showed severe biliary proliferation, without signs of active 
rejection. According with these results, it seems possible 
to correlate the failure of the liver grafts to the damage 
induced by the first humoral attack of the natural and 
induced antibodies. mainly focalized in the biliary tract. 8 
This is in agreement with the observation that, after liver 
xenotransplantation. when FK 506 is combined with a 
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drug that effectively prevents antibody production (an-
tiproliferative drugs), we have never observed a hepatic 
failure with the characteristics described above.9 
Paradoxically, after liver xenotransplantation, the ani-
mals receiving Spx + FK 506 2 mglkg/d had higher 
mortality than the other groups. One explanation could be 
that high levels of FK 506 present in these rats increase the 
production of IL-IO. 10 a potent growth and differentiation 
factor for activated T-independent B lymphocytes. I I 
The hyperacute rejection of long-term surviving cardiac 
xenografts after injection with hyperimmune serum indi-
cates that the vascular endothelium of the graft remains 
susceptible to humoral injury. 
The liver seems to be more antigenic than the heart, as 
indicated by the huge splenomegaly.4 the massive splenic 
lymphocyte proliferation,2 and the very high cytotoxic 
titer observed after liver xenotransplantation. This would 
explain the slight improvement in survival of liver xe-
nograft recipients. In conclusion. Spx + FK 506 can 
overcome the antibody barrier in the hamster-to-rat car-
diac xenograft model with excellent graft survival. 
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